Allogene Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Allogene Therapeutics, Inc. (ALLO) reported Basic Shares Outstanding (Weighted Average) of 328.93 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 328.93M shares, a 50.24% increase year-over-year.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 240.29M shares, a 11.58% increase year-over-year.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 226.09M shares, a 7.31% increase year-over-year.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 222.04M shares, a 6.14% increase year-over-year.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 220.62M shares, a 13.25% increase from fiscal 2024.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 194.81M shares, a 24.14% increase from fiscal 2023.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 156.93M shares, a 9.63% increase from fiscal 2022.
- Allogene Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 143.15M shares, a 5.39% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 328.93M shares 10-Q · filed 2026-08-12 | 284.86M shares 10-Q · filed 2026-08-12 | 265.10M shares derived: average of 3 quarters · filed 2026-08-12 | 254.34M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 240.29M shares 10-Q · filed 2026-05-13 | 233.19M shares derived: average of 2 quarters · filed 2026-05-13 | 229.47M shares derived: average of 3 quarters · filed 2026-05-13 | 226.84M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 226.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 224.06M shares derived: average of 2 quarters · filed 2026-03-12 | 222.35M shares derived: average of 3 quarters · filed 2026-08-12 | 220.62M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 222.04M shares 10-Q · filed 2025-11-06 | 220.48M shares derived: average of 2 quarters · filed 2026-08-12 | 218.80M shares 10-Q · filed 2025-11-06 | 216.75M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 218.93M shares 10-Q · filed 2026-08-12 | 217.15M shares 10-Q · filed 2026-08-12 | 214.99M shares derived: average of 3 quarters · filed 2026-08-12 | 213.54M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 215.36M shares 10-Q · filed 2026-05-13 | 213.02M shares derived: average of 2 quarters · filed 2026-05-13 | 211.74M shares derived: average of 3 quarters · filed 2026-05-13 | 206.32M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 210.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 209.94M shares derived: average of 2 quarters · filed 2026-03-12 | 203.30M shares derived: average of 3 quarters · filed 2026-03-12 | 194.81M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 209.19M shares 10-Q · filed 2025-11-06 | 199.61M shares derived: average of 2 quarters · filed 2025-11-06 | 189.52M shares 10-Q · filed 2025-11-06 | 184.20M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 190.03M shares 10-Q · filed 2025-08-13 | 179.58M shares 10-Q · filed 2025-08-13 | 175.87M shares derived: average of 3 quarters · filed 2025-08-13 | 173.82M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 169.13M shares 10-Q · filed 2025-05-13 | 168.80M shares derived: average of 2 quarters · filed 2025-05-13 | 168.41M shares derived: average of 3 quarters · filed 2025-05-13 | 163.01M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 168.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 168.06M shares derived: average of 2 quarters · filed 2025-03-13 | 160.97M shares derived: average of 3 quarters · filed 2025-03-13 | 156.93M shares 10-K · filed 2025-03-13 |
| 2023-09-30 | 167.65M shares 10-Q · filed 2024-11-07 | 157.22M shares derived: average of 2 quarters · filed 2024-11-07 | 153.09M shares 10-Q · filed 2024-11-07 | 150.79M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 146.80M shares 10-Q · filed 2024-08-07 | 145.69M shares 10-Q · filed 2024-08-07 | 145.17M shares derived: average of 3 quarters · filed 2024-08-07 | 144.80M shares derived: average of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | 144.56M shares 10-Q · filed 2024-05-13 | 144.36M shares derived: average of 2 quarters · filed 2024-05-13 | 144.13M shares derived: average of 3 quarters · filed 2024-05-13 | 143.94M shares derived: average of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | 144.16M shares derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | 143.91M shares derived: average of 2 quarters · filed 2024-03-14 | 143.74M shares derived: average of 3 quarters · filed 2024-03-14 | 143.15M shares 10-K/A · filed 2024-03-14 |
| 2022-09-30 | 143.66M shares 10-K · filed 2024-03-14 | 143.52M shares derived: average of 2 quarters · filed 2024-03-14 | 142.81M shares 10-K · filed 2024-03-14 | 141.90M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | 143.39M shares 10-K · filed 2024-03-14 | 142.38M shares 10-K · filed 2024-03-14 | 141.32M shares derived: average of 3 quarters · filed 2024-03-14 | 140.24M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | 141.36M shares 10-K · filed 2024-03-14 | 140.28M shares derived: average of 2 quarters · filed 2024-03-14 | 139.20M shares derived: average of 3 quarters · filed 2024-03-14 | 138.10M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | 139.21M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | 138.12M shares derived: average of 2 quarters · filed 2024-03-14 | 137.02M shares derived: average of 3 quarters · filed 2024-03-14 | 135.82M shares 10-K/A · filed 2024-03-14 |
| 2021-09-30 | 137.03M shares 10-Q · filed 2022-11-02 | 135.93M shares derived: average of 2 quarters · filed 2022-11-02 | 134.69M shares 10-Q · filed 2022-11-02 | 133.45M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | 134.83M shares 10-Q · filed 2022-08-09 | 133.50M shares 10-Q · filed 2022-08-09 | 132.26M shares derived: average of 3 quarters · filed 2024-03-14 | 130.98M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | 132.17M shares 10-Q · filed 2022-05-04 | 130.98M shares derived: average of 2 quarters · filed 2024-03-14 | 129.70M shares derived: average of 3 quarters · filed 2024-03-14 | 126.12M shares derived: average of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | 129.80M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | 128.47M shares derived: average of 2 quarters · filed 2024-03-14 | 124.11M shares derived: average of 3 quarters · filed 2024-03-14 | 120.37M shares 10-K/A · filed 2024-03-14 |
| 2020-09-30 | 127.14M shares 10-Q · filed 2021-11-04 | 121.26M shares derived: average of 2 quarters · filed 2021-11-04 | 117.23M shares 10-Q · filed 2021-11-04 | |
| 2020-06-30 | 115.38M shares 10-Q · filed 2021-08-04 | 112.16M shares 10-Q · filed 2021-08-04 | ||
| 2019-12-31 | 101.06M shares 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |